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Abstract
Introduction The role of chemotherapy alone in newly diagnosed WHO grade 2 oligodendroglioma after biopsy, incomplete 
or gross total resection remains controversial. We here analyze the clinical outcome of four patient cohorts being treated 
with either procarbazine, CCNU and vincristine (PCV) or temozolomide (TMZ) after biopsy, resection only, or wait-and-
scan after biopsy.
Methods Patients (n = 142) with molecularly defined oligodendroglioma (WHO 2016) were assigned to four cohorts: W&S, 
wait-and-scan after stereotactic biopsy (n = 59); RES, surgical resection only (n = 27); TMZ, temozolomide after biopsy 
(n = 26) or PCV (n = 30) after biopsy. Presurgical MRI T2 tumor volumes were obtained by manual segmentation. Pro-
gression-free survival (PFS), post-recurrence PFS (PR-PFS) and rate of histological progression to grade 3 were analyzed.
Results PFS was longest after PCV (9.1 years), compared to 5.1 years after W&S, 4.4 years after RES and 3.6 years after 
TMZ. The rate of histological progression from grade 2 to 3 within 10 years was 9% for the PCV, 29% for the W&S, 67% for 
the RES and 75% for the TMZ group (p = 0.01). In the W&S group, patients treated with PCV at first relapse had a longer 
PFS from intervention than those treated with TMZ (7.2 vs 4.0 years, p = 0.04). Multivariate analysis identified smaller tumor 
volume prior to any intervention (p = 0.02) to be prognostic for PFS.
Conclusions PCV chemotherapy alone is an effective treatment for WHO grade 2 oligodendroglioma, with long PFS and 
low rate of histological progression.
Keywords Resection · Chemotherapy · Imaging · Low-grade glioma
Introduction
Oligodendrogliomas occur predominantly in young to mid-
dle adulthood and often show a prolonged, indolent clinical 
course. The World Health Organization (WHO) histologi-
cally distinguishes diffuse, WHO grade 2 from anaplastic, 
WHO grade 3 oligodendroglioma, but grading criteria 
to distinguish grades 2 and 3 remain controversial [1–4]. 
Mutations of the isocitrate dehydrogenase (IDH) genes 1 or 
2 and codeletion of chromosomes 1p and 19p have become 
molecular prerequisites for a diagnosis of oligodendroglioma 
in 2016 [5].
Treatment options for WHO grade 2 oligodendroglioma 
comprise neurosurgical resection if safely feasible, radio-
therapy (RT), chemotherapy, surveillance strategies, and 
combinations thereof. If gross total resection is achieved, 
a wait-and-scan strategy might be pursued. In patients with 
incomplete resection or considered at high risk for tumor 
progression, e.g., because of higher age, radiotherapy (RT) 
followed by chemotherapy consisting of procarbazine, 
lomustine and vincristine (PCV) is recommended [6]. On 
a cautionary note, benefits in terms of overall survival need 
to be weighed carefully against long-term adverse effects 
including neurocognitive decline or secondary hematologi-
cal neoplasms [7–11]. In patients with incompletely resected 
or progressive oligodendrogliomas after resection, TMZ 
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alone showed promising results in deferring RT [12, 13]. 
In anaplastic oligodendrogliomas, TMZ did not achieve the 
same outcome as RT alone or RT plus TMZ [14, 15]. Studies 
investigating long-term outcome of patients suffering from 
WHO grade 2 oligodendroglioma treated with TMZ or PCV 
alone are lacking.
Deferring multimodal and aggressive therapies in young 
patients with intention to delay treatment-induced toxicity 
without jeopardizing long-term outcome would be of great 
benefit. Due to institutional multidisciplinary tumor board 
decisions adhering to such treatment concepts, we could 
investigate long-term outcome of four different treatment 
strategies omitting initial RT in WHO grade 2 oligoden-
droglioma in this study: resection only or, after stereotac-
tic biopsy, either a wait-and-scan strategy or chemotherapy 
using TMZ or PCV only.
Patients and methods
Patient evaluation and treatment
The database of the Department of Neurosurgery at the 
University Hospital Munich was screened for patients with 
newly diagnosed 1p/19q-codeleted WHO grade 2 glio-
mas between 2003 and 2019 (Fig. 1). Ethics approval was 
obtained by the Ethics Committee of the Ludwig Maximil-
ian University of Munich (project number 20-513). Diag-
nosis was defined as first histological confirmation of oligo-
dendroglioma through frame-based stereotactic biopsy or 
tumor resection. Initial symptoms leading to the diagnosis 
were assessed. In patients diagnosed due to reasons other 
than neurological symptoms consistent with site and vol-
ume of the oligodendroglioma, the diagnosis was termed 
“incidental”. Treatment decisions were based on interdis-
ciplinary brain tumor board recommendations and patient’s 
preference.
After exclusion of small treatment cohorts, four patient 
cohorts could be defined (Table 1; Fig. 1):
Fig. 1  Histological oligodendrogliomas, oligoastrocytomas and astro-
cytomas with 1p/19q codeletion between 2003 and 2019 were reclas-
sified. WHO grade 3 oligodendrogliomas, patients with partial tumor 
resection, patients with missing data and patients from small treat-
ment cohorts were excluded. Partial resection was defined as > 50% 
residual, postoperative T2 tumor volume. WHO World Health Organi-
zation, PC(V) procarbazine, CCNU and vincristine, TMZ temozolo-
mide
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• patients with biopsy and wait-and-scan strategy (W&S),
• patients with tumor resection (RES) and no further ther-
apy,
• patients with biopsy and PCV chemotherapy (PCV) and
• patients with biopsy and TMZ chemotherapy (TMZ).
Patients who received maximal safe resection within 3 
months after histological diagnosis through stereotactic 
biopsy were allocated to the resection only group. Extent of 
resection (EOR) was defined as absence of residual tumor 
volume on postoperative MRI scans that had to be obtained 
within 72 h after surgery. If residual tumor volume was less 
than 50% of the initial T2 tumor volume, EOR was termed 
“subtotal”. If no residual tumor volume was observed, EOR 
was termed “gross total resection” (GTR). “Partial” resec-
tion referred to residual tumor volumes of more than 50%. 
All patients from the WS, TMZ and PCV cohorts fall into 
the high-risk low grade glioma group, because all were 
diagnosed through biopsy and thus had high postoperative 
tumor burden [7]. In the RES group, 10 patients had under-
gone GTR and 5 were younger than 40 years of age (range 
31–39 years). Because of the risk of polyneuropathy and 
perceived lack of efficacy of tumors protected by the blood 
brain barrier, vincristine was not routinely added to pro-
carbazine and CCNU. Patients receiving PC or PCV were 
pooled (PC(V)). PC(V) was given for 6 cycles if tolerated 
[16, 17]. TMZ was given for 6 cycles according to standard 
protocols if tolerated [18]. In the TMZ cohort, a median 
of 6 and a mean of 8 cycles was completed (range 3–20 
cycles). In the PCV cohort, a median and mean of 6 cycles 
was administered (range 1–8 cycles). Clinical and imaging 
routine follow-up intervals were 3 to 6 months. Progres-
sion was defined retrospectively in accordance with RANO 
guidelines for low-grade gliomas as either clinical deterio-
ration not attributable to other causes apart from the tumor 
(I) or tumor growth (increase in perpendicular diameters 
of 25% or more; increase in 25% tumor volume or more) 
Table 1  Clinical and patient characteristics




TMZ only (n = 26) PC(V) only (n = 30) p-value
Age (years)
 Median 42 40 39 42 46 0.37
 Range 20–80 20–80 20–64 26–70 27–64
Sex, n (%)
 Female 74 (52%) 34 (58%) 7 (26%) 14 (54%) 13 (43%) 0.04*
 Male 68 (48%) 25 (42%) 20 (74%) 12 (46%) 17 (57%)
KPS
 ≥ 80 138 (97%) 57 (97%) 27 (100%) 24 (92%) 30 (100%) 0.26
 < 80 4 (3%) 2 (3%) 0 (0%) 2 (8%) 0 (0%)
Trigger for diagnostic work-up
 Incidental finding 29 (20%) 16 (27%) 4 (15%) 3 (12%) 6 (20%)
 Seizure 98 (69%) 40 (68%) 20 (74%) 18 (69%) 20 (67%) 0.36
 Neurological deficit 15 (11%) 3 (5%) 3 (11%) 5 (19%) 4 (13%)
Localization, n (%)
 Frontal 74 (52%) 24 (41%) 21 (78%) 17 (65%) 12 (40%)
 Temporal 33 (23%) 19 (32%) 2 (7%) 4 (15%) 8 (27%)
 Insular 16 (11%) 7 (12%) 1 (4%) 3 (12%) 5 (17%)
 Parietal 15 (11%) 7 (12%) 3 (11%) 0 (0%) 5 (17%) 0.09
 Occipital 1 (1%) 0 (0%) 0 (0%) 1 (4%) 0 (0%)
 Cingulate 1 (1%) 1 (2%) 0 (0%) 0 (0%) 0 (0%)
 Midline 2 (1%) 1 (2%) 0 (0%) 1 (4%) 0 (0%)
Laterality, n (%)
 Left 70 (49%) 34 (58%) 12 (44%) 10 (39%) 14 (47%)
 Right 67 (47%) 25 (42%) 15 (56%) 13 (50%) 14 (47%) 0.09
 Bilateral 5 (4%) 0 (0%) 0 (0%) 3 (12%) 2 (7%)
Initial T2 volume  (cm3)
 Median 42 24 47 76 52  < 0.01*
 Range 3–374 3–247 10–171 13–374 6–311
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on T2 weighted MRI (II) [19]. In patients with suspicious, 
new MRI foci, e.g. new contrast enhancement, progression 
was assumed if a stereotactic biopsy of the focus confirmed 
glioma tissue (III). Adverse events were classified retrospec-
tively according to the Common Terminology Criteria for 
Adverse Events 5.0 (CTCAE 5.0).
Histology and molecular status
All oligodendrogliomas in this study were re-evaluated by an 
experienced neuropathologist (R.E.) according to the WHO 
classification 2016 and only patients with tumors classified 
histologically and molecularly as oligodendroglioma WHO 
grade 2 were included (Fig. 1) [5]. Microsatellite markers 
were utilized for confirmation of 1p/19q codeletion (chro-
mosome 1p: D1S1608, D1S1592, D1S548, D1S1161, 
D1S1184; chromosome 19q: D19S718, D19S433, D19S601, 
D19S559, D19S431). For the IDH1 gene, an 88 base-pair 
long fragment and for IDH2 gene, an 83 base-pair long frag-
ment were subjected to pyrosequencing to detect hotspot 
mutations at codon 132 for IDH1 or codon 172 for IDH2 
[20]. MGMT promoter methylation has been investigated 
in 120 of 144 patients from our cohort through methyla-
tion specific PCR analysis [21]. Malignant progression was 
defined as histologically confirmed progression from WHO 
grade 2 to WHO grade 3.
Volumetric assessment, matching and statistics
Pre-therapeutic tumor volumes were obtained through man-
ual segmentation of T2-weighted sequences utilizing Brain-
Lab Elements Smartbrush Software. In patients treated with 
chemotherapy, posttherapeutic MRI scans obtained within 1 
month after completion of the last cycle were investigated. 
In our center, post-therapeutic imaging is not routinely trans-
ferred to the databases, hence T2 imaging for comparative 
pre- and post-therapeutic manual volume segmentation were 
only obtained in 27 patients (48%) treated with chemother-
apy (Supplementary Fig. 2). Radiological reports of vol-
ume status were available in 53 out of 56 patients receiving 
chemotherapy (95%).
For a matched-pair analysis of the TMZ and PC(V) 
groups, oligodendrogliomas were matched according to 
initial T2 tumor volume. Patients were paired only if the 
initial tumor volumes did not differ by more than 10% of the 
larger volume of the pair (Supplementary Table 1). Malig-
nant progression rates and progression-free, post-recurrence 
and overall survival were evaluated through Kaplan–Meier 
estimator method. T-tests and ANOVA were used for para-
metric comparative testing of continuous variables in two 
or more groups. For categorical variables, chi-square test 
was used. Results were termed significant if p-values were 
lower than 0.05. For comparison of interactions, log-rank 
tests and Cox regression hazards models for multivariate 
analyses were used. Tests were performed using IBM SPSS 
25.0 and GraphPad Prism 8.4.2 software.
Results
Study population and baseline characteristics
We identified 142 patients. Median age at diagnosis was 
42 years (range 20–80 years). 137 Patients (97%) had an 
initial Karnofsky performance status (KPS) of 80 or higher 
(Table 1). All patients were retrospectively assigned to the 
following groups: wait-and-scan surveillance after biopsy 
(n = 59); surgical tumor resection (n = 27, including 10 
patients with complete resection and 17 patients with sub-
total resection); TMZ chemotherapy after biopsy (n = 26); 
and PCV chemotherapy after biopsy (n = 30; including 20 
patients who received PC only). Methylated MGMT pro-
motor was investigated in 120 patients and detected in 117 
patients.
Preoperative MRI scans were available in 113 patients 
(80%). Initial tumor volumes were largest in the TMZ and 
smallest in W&S group (p < 0.001). In W&S, the proportion 
of patients with incidental diagnoses was higher than in the 
other groups. Seizures were the most prevalent trigger for 
diagnostic work-up. Male patients were more often managed 
by resection alone than female patients (Table 1).
Outcome
Progression was documented in 88 patients (62%) and deter-
mined through tumor growth on conventional MRI in 64 
patients. In 6 patients, progression was determined through 
neurological decline and in 18 patients through stereotactic 
biopsies of new T2 hyperintense or T1 contrast-enhancing 
foci confirming recurrence or progression. 54 Patients did 
not progress after a median follow-up of 67 months. During 
the overall clinical course, repeated histological sampling 
through biopsy or resection was performed in 64 patients. 
Histological progression from WHO grade 2 to 3 was 
observed in 20 of these patients.
Follow-up time ranged from 0.2 to 16 years with a mean 
FU of 6.5 years and a median FU of 5.9 years. 34 patients 
had a FU of 10 years or longer. Median overall survival 
was not reached. 5 Patients have died overall [PC(V), n = 0; 
W&S, n = 1; RES, n = 3; TMZ, n = 1]. Causes of death were 
tumor-related in all patients. Progression-free survival (PFS) 
and malignization rates (MR) at different time points per 
group are summarized in Table 2.
Patients treated with PC(V) showed the best outcome 
with a median PFS of 9.1 years. Only 1 out of 30 patients 
underwent histological progression from WHO grade 2 to 3.
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The shortest PFS was seen in TMZ (median 3.6 years). 
PFS of W&S and RES was 5.1 years and 4.4 years (Fig. 2). 
Patients with gross total resection (n = 10) had a PFS of 
6.1 years versus 2.5 years in patients with subtotal resec-
tion (n = 17) (p = 0.27) and residual tumor volumes ranged 
from 0.31 to 53.00  cm3 (median 6.28  cm3; mean 12.54 
 cm3). In the PC(V) group, malignant transformation from 
WHO 2 to 3 occurred at a significantly lower rate than in 
the W&S and RES groups. In RES, malignant transforma-
tion occurred more often than in W&S (p = 0.04).
Small initial T2 volumes were associated with an over-
all favorable outcome. A matched-pair analysis of tumor 
volumes in patients treated with TMZ or PC(V) was per-
formed (Fig. 2c; Supplementary Table 1). The results 
suggested superiority of PC(V) over TMZ with a median 
PFS of 9.1 vs 4.7 years (p = 0.03, HR = 3.0, 95% CI for 
HR 1.2–8.1). An overall analysis of oligodendrogliomas 
smaller than 80  cm3 showed longest PFS in PC(V) (in 
years, 5.1 in W&S versus 3.2 in RES versus 6.8 in TMZ 
versus 10.9 in PC(V)), however, this analysis did not reach 
statistical significance potentially due to small sample size 
(p = 0.27).
An analysis of salvage therapy for progressive gliomas 
of the W&S group showed superiority of PC(V) over TMZ 
(Fig. 2d) at first recurrence. In W&S, treatment choice 
in case of recurrence was mostly chemotherapy with 17 
patients (44% of progressive oligodendrogliomas in W&S) 
receiving TMZ and 10 patients (26%) receiving PC(V) at 
first progression (Supplementary Fig. 1). Post-recurrence 
PFS (PR-PFS) was 4.0 years for TMZ and 7.2 years for 
PC(V) (p = 0.04) (Fig. 2d).
Univariate analyses were performed for PFS and time-
to-malignization including the factors age, KPS, initial 
therapy and initial T2 tumor volume. Smaller initial T2 
volumes correlated with longer PFS. PC(V) therapy was 
associated with longer PFS as compared to resection only 
or TMZ only and showed significantly longer time-to-
malignization than resection only (Table 3). Subsequent 
multivariate analyses confirmed initial tumor volume 
to be prognostic for PFS (p = 0.02, HR = 1.01, 95% CI 
1.01–1.02). Multivariate analyses for TTM were not per-
formed due to the low number of events.
Table 2  Progression-free survival and time-to-malignization—outcome by initial strategy
TMZ temozolomide, PC(V) procarbazine, CCNU and vincristine, n.r. not reached





TMZ only (n = 26) PCV only (n = 30)
Median Median Median Median Median
Progression-free survival 
(years)
5 5.1 4.4 3.6 9.1
n Events Rate n Events Rate n Events Rate n Events Rate n Events Rate
1 year 122 17 14 49 7 14 24 4 17 24 2 8 25 4 16
2 years 116 34 29 48 13 27 23 7 30 23 8 35 22 6 27
5 years 98 63 64 42 28 67 21 14 67 17 14 70 18 7 39
10 years 93 83 89 40 37 93 19 18 95 17 17 100 17 11 65
15 years 90 88 98 40 38 95 18 18 100 17 17 100 15 15 100





TMZ only (n = 26) PCV only (n = 30)
Median Median Median Median Median
Time-to-malignization (years) n.r n.r 8.7 n.r n.r
Malignization rate (%) n Events Rate n Events Rate n Events Rate n Events Rate n Events Rate
1 year 122 1 1 49 0 0 24 1 4 25 0 0 24 0 0
2 years 112 4 4 47 1 2 21 1 5 23 1 4 21 1 5
5 years 77 10 13 36 3 8 15 3 20 14 3 21 12 1 8
10 years 45 16 36 21 6 29 9 6 67 4 3 75 11 1 9
15 years 27 20 74 15 9 60 7 7 100 3 3 100 2 1 50
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Volume change during chemotherapy
There was no reported tumor growth during chemotherapy. 
In patients treated with PC(V), a stable tumor volume after 
therapy completion was reported in 5 patients (17%). Stable 
was defined as no apparent volume change on MRI. Volume 
reduction, defined as median proportional decrease of T2 
tumor volume after therapy when compared to pre-thera-
peutic imaging in percentages, was 49% (range 12–71%). In 
the TMZ cohort, a stable tumor volume was reported in 4 
patients (15%) and median volume reduction of those with 
available post-therapeutic MRI was 39% (range 9–62%) 
(Supplementary Fig. 2).
Adverse events
Adverse events were documented in 23 of 56 patients (41%). 
Severe adverse events (SAE), i.e. CTCAE grade 3–5 AE, 
that led to transient or permanent discontinuation of therapy, 
were seen in 11 patients (20%). Out of 10 patients treated 
with PCV, 4 (40%) developed SAEs and out of 20 patients 
treated with PC, 3 (15%) developed SAEs. SAEs were seen 
in 4 patients (15%) out of 26 receiving TMZ (Supplementary 
Fig. 3).
In patients receiving PCV, SAEs were reported in 40%, 
whereas only 15% of patients treated with PC or TMZ devel-
oped SAEs (Supplementary Fig. 3). This higher percentage 
could be attributed to peripheral sensory neuropathy, a well-
known potential side effect from vincristine.
Discussion
Patients suffering from oligodendroglioma can survive for 
decades [22]. Histological and molecular diagnostic cri-
teria have changed over the last years. Several treatment 
options including different surgical strategies, radiotherapy 
techniques and alkylating agent chemotherapy protocols 
Fig. 2  Overall progression-free survival (PFS, p = 0.05) (a), time-
to-malignization (TTM, p =0.04*) (b), PFS of T2-volume matched 
patients treated with temozolomide (TMZ) or procarbazine + CCNU 
(+/− vincristine) (PC(V)) (p = 0.03*) (c) and post-recurrence PFS (p 
= 0.04*) (d) of patients from the wait-and-scan cohort treated with 
TMZ or PC(V) at first progression. For a and b, four different groups 
were compared: wait-and-scan versus resection only versus temozo-
lomide only versus procarbazine + CCNU (+/− vincristine) (PC(V)) 
only. For c and d patients treated with TMZ or PC(V) were compared
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are available and increasingly used in combination [6]. 
Treatment-induced toxicity must be weighed carefully 
when selecting type and timing of tumor-specific treatment. 
Here, we investigated long-term clinical course with differ-
ent therapeutic approaches.
Our data strongly suggest that among the preferred treat-
ments for WHO grade oligodendroglioma at our site, PC(V) 
is the best initial monotherapy. We find that PC(V) after 
biopsy leads to better PFS than resection only or than TMZ 
after biopsy. PC(V) was associated with significantly lower 
malignization rates than wait-and-scan strategies or tumor 
resection with only one affected patient. Superiority of 
PC(V) over TMZ was further supported by a matched-pair 
analysis of patients treated with PC(V) versus TMZ. Addi-
tionally, patients from the W&S cohort treated with PC(V) 
at first progression showed a longer PFS than those treated 
with TMZ at first progression.
Smaller initial tumor volumes were associated with 
longer PFS, matching results from a prior publication of 
oligodendroglioma volumes [23]. This may in part explain 
the poor overall outcome in the TMZ group that had the 
largest median initial tumor volume. Worse outcome in 
patients with larger initial tumor volumes may also explain 
why, counterintuitively, PFS was shorter in RES than in 
W&S with a median initial tumor volume twice as large. 
The criterion that any new lesion is considered as progres-
sive disease might lead to a quicker call of progression in 
patients receiving tumor resections, e.g. when observing new 
lesions bordering the resection cavity. Conversely, marginal, 
3-dimensional tumor growth in patients with large tumors 
is not accounted for if not exceeding 25% or more of largest 
perpendicular diameters.
Standard therapy for oligodendroglioma grade 2 by con-
sensus is tumor resection if safely feasible [18]. Whether or 
not treatment beyond surgery is initiated depends on various 
factors, including the extent of residual tumor volume. Many 
patients included in this study would be treated differently 
nowadays, e.g. patients with frontal oligodendrogliomas 
and biopsy only. As many patients included were diagnosed 
before the era of molecular classification and KPS was gen-
erally high, interdisciplinary tumor boards back then often-
times left scope for mono-chemotherapies which was openly 
discussed with the patients. Cultural differences might have 
played a role in deferring surgery or radiotherapy in many 
patients. A retrospective study found that greater extent of 
resection (EOR) correlated with favorable outcome in oli-
godendroglioma grade 2 but did not delay time to malignant 
transformation [24]. This is in line with our findings. The 
fact that malignization rates were significantly higher in RES 
than in W&S might be explained by the fact that patients in 
the W&S group were treated far more often with PCV at first 
progression than patients in RES (Supplementary Fig. 1) and 
that RES patients had larger volumes initially.
PCV alone or following radiotherapy is a well-established 
therapy in the treatment of oligodendroglioma. In this study, 
superiority of PC(V) over TMZ and RES in terms of PFS 
was observed in the long-term. There were multiple crosso-
vers in Kaplan–Meier curves of PFS within the first 2 years 
Table 3  Uni- and multivariate analyses
Other strategy = wait-and-scan, resection only and TMZ. Statistical significance (p < 0.05) is depicted by asterisks (*)
KPS Karnofsky performance score, TMZ temozolomide, PC(V) procarbazine, CCNU and vincristine
Univariate analysis of PFS and TTM
Parameter PFS TTM
HR 95% CI p-value HR 95% CI p-value
Age 0.99 0.97–1.01 0.44 1.00 0.97–1.04 0.84
KPS 0.99 0.96–1.03 0.77 1.03 0.94–1.12 0.58
Wait-and-scan vs resection 0.78 0.43–1.42 0.42 0.29 0.09–0.96 0.04*
Resection vs chemotherapy 1.47 0.79–2.74 0.22 4.99 1.37–18.22 0.02*
Resection vs TMZ 1.03 0.53–2.00 0.94 2.10 0.60–7.39 0.25
Resection vs PC(V) 2.12 1.02–4.40 0.04* 7.38 1.75–31.05 0.01*
TMZ vs PC(V) 2.29 1.05–4.98 0.04* 2.66 0.37–18.85 0.33
Other strategy vs PC(V) 1.67 1.01–2.75 0.05* 2.84 1.01–8.11 0.05*
T2 volume 1.01 1.01–1.02 0.05* 1.00 0.99–1.01 0.94
Multivariate analysis of PFS: backwards (Wald)
Parameter PFS
HR 95% CI p-value
T2 volume 1.01 1.01–1.02 0.02*
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of diagnosis, e.g. between W&S and PC(V). This might hint 
at a subgroup of WHO grade 2 oligodendrogliomas that are 
refractory to PC(V) chemotherapy or to challenges in deter-
mining progression in patients exhibiting minor changes on 
MRI.
As PC(V) and TMZ both reduced initial T2 tumor vol-
ume, their potential as “neoadjuvant” presurgical therapy 
and the question if volume decrease after chemotherapy 
might be a marker for outcome require further evalua-
tion. Radiotherapy with sequential PCV chemotherapy is 
an exceptionally effective therapy for WHO grade 2 and 3 
oligodendroglioma as shown by prospective, clinical trials 
[16, 25–27]. The question whether early radiotherapy in 
initially smaller tumors is superior as compared to delayed 
radiotherapy in larger tumors remains unanswered. In our 
data set of oligodendroglioma grade 2 diagnosed between 
2003 and 2019, only 5 patients (4%) died from tumor-related 
death and the question remains if invasive treatment regi-
mens comprising resection and radiotherapy with sequential 
chemotherapy are warranted in these tumors.
Important limitations of the present study are its retro-
spective nature and the small sample size in some subgroups. 
Although overall survival was not reached in this study, pro-
spective clinical trials of anaplastic oligodendroglioma have 
shown that in the long-term, prolonged PFS translates into 
superior OS [16, 25]. Strengths of this study comprise the 
standardized histological and molecular classification of all 
oligodendrogliomas according to WHO 2016, investigation 
of initial tumor volumes, long follow-up intervals and high 
rate of repeated histological sampling, providing information 
on malignant transformation.
In summary, our data strongly suggest that PCV chemo-
therapy is an important compound in the treatment of WHO 
grade 2 oligodendroglioma after biopsy or resection due to 
its superiority in prolonging PFS and potentially delaying 
malignant progression.
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